UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 9, 2016
ADURO BIOTECH, INC.
(Exact name of registrant as specified in its charter)
| | | | |
| Delaware | | 001-37345 | | 94-3348934 |
(State or Other Jurisdiction of Incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
626 Bancroft Way, 3C
Berkeley, California 94710
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: (510) 848-4400
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Section 5—Corporate Governance and Management
Item 5.07 Submission of Matters to a Vote of Security Holders.
Set forth below are the proposals voted upon at the Annual Meeting (the “Annual Meeting”) of Stockholders of Aduro Biotech, Inc. (the “Company”) held on June 9, 2016 at 626 Bancroft Way, 3C, California 94710, along with the final voting results thereon:
Proposal 1—To elect the three Class I directors named below to serve until the 2019 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified. Each of the three named nominees was so elected, with the votes thereon at the Annual Meeting as follows:
| | | | | | | | | | | | |
| | | Final Voting Results | |
Nominees | | For | | | Withheld | | | Broker
Non-Votes | |
Stephen T. Isaacs | | | 46,500,922 | | | | 1,492,553 | | | | 5,433,454 | |
William M. Greenman | | | 46,230,348 | | | | 1,763,127 | | | | 5,433,454 | |
Stephen A. Sherwin, M.D. | | | 47,730,285 | | | | 263,190 | | | | 5,433,454 | |
Proposal 2—To ratify the selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2016. This proposal was approved by the requisite vote, with the votes thereon at the Annual Meeting as follows:
| | | | | | |
Final Voting Results |
For | | Against | | Abstain | | BrokerNon-Votes |
53,067,141 | | 351,046 | | 8,742 | | — |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | |
| | | | ADURO BIOTECH, INC. |
| | | |
| Dated: June 10, 2016 | | | | By: | | /s/ Jennifer Lew |
| | | | | | Jennifer Lew |
| | | | | | Senior Vice President of Finance |
